Key Takeaways
- H1 profit surpasses prior full-year marks: PAT of INR 311 crores in H1 FY26 alone exceeded the full-year PAT of FY22, while H1 revenue of INR 1,098 crores topped FY21’s full-year revenue.
- Margins expanded faster than revenue: EBITDA margin grew 18.2% against 11% revenue growth, driven by operating leverage and cost discipline; PAT margin reached 28.3%, well ahead of the 25% target.
- US subsidiary broke even in its first quarter: Caplin Steriles (CSU) turned profitable within months of launch, a milestone management had originally targeted for its second year of operation.
- A pipeline build, not a revenue surge yet: The quarter was defined by regulatory filings, facility completions, and ANDA acquisitions across Mexico, Chile, and the US, with the payoff from larger geographies still 18–24 months away.
- What to watch next quarter: Whether the oncology injectable facility secures an INVIMA inspection date, the pace of ANDA acquisitions toward the 45–46 target, and any concrete acquisition announcement given the INR 1,300+ crore cash reserve.
The Pipeline Build: Facilities, Filings & ANDAs
- Oncology injectable facility now online: The facility has come on stream and exhibit batches for developed products are underway; an INVIMA audit has been applied for, with inspection expected sometime next year.
- COL injectables nearing completion: Caplin One Lab’s INR 90 crore injection project is in final stages and likely to go on stream by December; Phase III will add 5 more lines dedicated to the US market, positioning Caplin among the top 4–5 injectable exporters from India.
- ANDAs stockpile growing: Four ANDAs acquired so far, with 5 more in process and expected in the coming weeks, which would bring the total to around 45–46.
- Mexico pipeline accelerating: 35+ products filed in Mexico with 20 approvals already secured alongside partners; a larger pipeline of 80–90 products is targeted for filing within the next 12 months, drawing on internal products and partner ANDAs from China.
- Prefilled syringes and cartridges in advanced development: 11 prefilled syringe products are at advanced stages, with plans to file almost all by next financial year; cartridges, including GLP-1 products, are being added from the same line.
- GLP-1 first-wave positioning: Dossiers for GLP-1 products have been filed in four Latin American countries, aiming to be in the first wave of generics when patents expire.
- Outsourcing to free capacity: The company has begun outsourcing two products to a quality-conscious South Indian manufacturer and is discussing moving more, reserving in-house capacity for high-value, tricky, or complex products until COL Phase III capacity comes online.
C. C. Paarthipan: "That's why I said the next two years is not going to be the bedrock of our future business. The bedrock actually is in the form of work in progress. Once it starts rectifying, you will see something different."
US & Regulated Markets: Early Traction, Long Runway
- US front-end outperforming expectations: Management admitted the company never expected to do so well in the US front-end so fast; it is now actively acquiring brands and ANDAs.
- CSU profitability surprised positively: Caplin Steriles broke even within its first quarter of operation and is now profitable, with margins very similar to the parent companies; 24 products were launched within the first 12 months.
- Consolidated US PBT actually rose: An analyst flagged a year-on-year PBT decline in the US segment, but management clarified that CSL plus CSU consolidated PBT increased to INR 20.2 crores from INR 17.13 crores last year, and that CSU is only nine months old so quarter-to-quarter comparisons are premature.
- Phase III injectable facility is the US bet: The COL injectable facility’s Phase III will house 5 lines dedicated to the US market; combined with CSL’s existing lines, Caplin will operate 12 injectable lines, making it one of the few Indian exporters with that scale.
- Protectionism driving onshoring plans: The company is planning facilities overseas, including in Mexico, Guatemala, and possibly one in the US, because “the world is moving towards protectionism.”
LatAm & Larger Geographies: The 24-Month Growth Thesis
- Larger markets will take time to convert: Registrations and biostudies in Mexico, Colombia, and Chile mean business in these larger geographies will probably start only by Q4 of next year; the opportunity is multifold because incumbents carry high overheads.
- 20–25% growth pinned to 24 months out: When pressed on timing, management committed that 20–25% growth “will definitely happen” 24 months from the call date, not 18 months.
- 40% operating margin is conditional: Management said 40% operating margin is “definitely possible” after two years, but only if markets are not totally commoditized and if adverse government policies do not intervene.
- Institution business emerging in smaller geographies: Lucrative institutional opportunities have recently appeared in smaller geographies, and management expects the same pattern to repeat in larger ones.
- Chile warehousing now operational: The company has started warehousing for both private market sales and local tender sales in Chile, deepening its in-country presence.
C. C. Paarthipan: "After two years, yes, it's definitely possible, if the markets are not commoditized totally, because that's one thing you know. And then if the rulers don't come with some policy like what has happened today to some other industry, that's the reason today, probably individual excellence has to outplace or outscore actually the politics."
Business Model Moat: Private Market Control & Vertical Integration
- Private market dominance limits receivables risk: 70–75% of business is private market where the company controls supply; if a customer does not pay, Caplin can stop supply because customers cannot find alternatives for 150–200 products.
- Non-regulated market expertise is rare: Management argued that most generic companies have not made money in non-regulated markets because of the risk of entering smaller geographies; Caplin entered Latin America 20–21 years ago when few Indians and Chinese were present and has built 500–600 products across most smaller markets.
- Backward integration is about supply continuity, not just cost: For injectables and ophthalmics, API quantity per product is tiny (10–20 mg vs 500–700 mg in oral solids), so owning API ensures availability and avoids disruption when third-party API suppliers receive warning letters.
- Currency risk managed without derivatives: The company does not use derivatives; it keeps goods in warehouses so if receivables take a beating from currency moves, it can increase prices of warehouse goods to offset the loss; 35% of products go out of China, providing a natural hedge, and some operating countries use the US dollar as local currency.
- No currency losses to date: Management stated the company has “not lost INR 1 on account of currency rates” and has been gaining substantially over time; the INR 47 crores translation gain over 12 quarters is a notional OCI item, not included in PAT.
C. C. Paarthipan: "If you look at other companies, most of the companies which are doing well, you will not be able to find one company which has made money in a nonregulated market in generic. That's because no company has to take a risk actually, it is risk to go to these types of smaller geographies."
Capital Allocation: Cash Pile, No Payout, Waiting for the Right Deal
- INR 1,300+ crore cash reserve, no distribution planned: When an analyst asked whether excess cash should be returned via dividends or buybacks, management said it needs to keep cash in reserve for meaningful acquisition opportunities.
- Acquisition evaluation is active but selective: The company gets opportunities almost weekly and is evaluating what fits its growth path toward larger LatAm markets, the US, and its distribution model; a specific PE-backed opportunity (USD 200 million company, INR 30 crore investment for 20% stake) was rejected after due diligence revealed it was not a meaningful fit.
- Acquisition wish list is broad: Potential targets include a distribution chain to understand market mechanics in 1–1.5 years, a startup or midsize Chinese company supplying biological products, a US company manufacturing controlled drugs, or an OTC brand in Latin America/Mexico that other products could piggyback on.
- No borrowing, all growth self-funded: Both capex and opex are managed from own cash accruals, and management hopes to remain debt-free for the near future; a slightly longer working capital cycle is tolerable because there is no interest cost.
Vivek Partheeban: "On paper, it was excellent numbers. In fact, the size of the acquisition was a significant one, and we were open to it. But once you started peeling away the layers and understanding the next 5 years, it just didn't seem like what we expected it to be."
Working Capital & Geopolitical Friction
- Receivables at 117 days, targeting below 120: The company is working to keep receivables under 120 days; government payment delays can stretch to 120 days or more, but government will not deny payment.
- Geopolitical turbulence slowing container movement: Turbulence near Yemen and tariff-related uncertainty have affected container movement, taking more time to reach destinations; when government orders are delayed in supply, payment also gets delayed.
- Cash conversion cycle may drift but without losses: Management acknowledged the cycle may go a little up or down but insisted it will not result in inventory loss or receivables loss, citing private market control and the absence of borrowing.
- Tariff status remains unchanged: The company is still exempted from tariffs and is “in the same boat as everybody else”; management noted that generic products are not tariffed and nothing from the new US administration has mentioned generics being subject to tariffs.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| COL injectables on stream | INR 90 crore injection project goes live | Probably by December (current FY) |
| ANDA count target | Reach 45–46 ANDAs once 5 more acquisitions close | Coming few weeks |
| Prefilled syringe filings | File almost all 11 advanced-stage products | By next financial year |
| Mexico product filings | File 80–90 products in Mexico | Within next 12 months |
| CSU own-label launches | Launch another 15 products under own label | Next financial year |
| Oncology API facility completion | Facility completed | Next year |
| Larger LatAm market entry | Business in Mexico, Colombia, Chile begins | Q4 of next year |
| 20–25% revenue growth | Growth rate accelerates to 20–25% | 24 months from call date |
| 40% operating margin | Achieve 40% margin, conditional on market and policy environment | After two years |
Key Metrics
| Metric | Q2 FY26 |
|---|---|
| Operating revenue growth | 11% YoY |
| Total income growth | 12% YoY |
| H1 revenue | ₹1,098 cr, exceeding full-year FY21 revenue of ₹1,085 cr |
| Other income | ₹14.18 cr, primarily from deployment of incremental cash |
| EBITDA growth | 18.2% YoY, above revenue growth |
| EBITDA margin | Not stated as a percentage; Opex as a percentage of total revenue was 24.8% vs 25.6% last year |
| PBT | ₹385.5 cr, +19.4% YoY from ₹322.8 cr; PBT margin 35.1% vs 32.9% last year |
| PAT | ₹311 cr, +21.6% YoY; PAT margin 28.3% vs 26.1% last year |
| Net worth | ₹3,159 cr, crossing ₹3,000 cr mark |
| Liquid assets | ₹2,358 cr, exceeding annual revenue |
| Cash and cash equivalents | ₹1,334 cr, vs ₹1,180 cr as of March 2025 |
| Capitalization during H1 | ₹48 cr, with additional ₹2 cr of depreciation |
| WIP (Work in Progress) | ₹174 cr, of which Caplin One Lab injection projects ~₹90 cr |
| Receivables | 117 days, vs 118 days as of March 2025 |
| Cash flow from operations (H1) | ₹254 cr, vs ₹186 cr in corresponding period last year |
| Free cash flow after capex (H1) | ₹160 cr, vs ₹109 cr in corresponding period last year |
| Caplin Steriles (CSL + CSU) consolidated PBT | ₹20.2 cr, vs ₹17.13 cr last year |
| Caplin Steriles EBITDA | ₹37.2 cr |
| ANDAs (acquired + in process) | 4 acquired, 5 more in process; expected to reach 45–46 total |
| CSU products launched | 24 within first 12 months; targeting 15 more next financial year |
| Mexico product filings | 35+ filed, 20 approvals; pipeline of 80–90 to be filed within 12 months |
| Chile product licenses | 125 |
| Products at advanced development stages | 11, planned for filing by next financial year |
| Inventory at customer locations and in transit | 67% of total inventory |
| Private market share of business | 70–75% |